Bayer plays white knight for Schering

Article

Merck is out and Bayer is in, as the race to win the corporate hand of Schering appears to be over. Representatives of the Berlin-based contrast media giant were nonplussed from the start with Merck’s bid, which Schering executives said undervalued the company.

Merck is out and Bayer is in, as the race to win the corporate hand of Schering appears to be over. Representatives of the Berlin-based contrast media giant were nonplussed from the start with Merck's bid, which Schering executives said undervalued the company.

Predictions that Schering would accept only a bid 30% to 35% above the closing price on March 10 (DISCAN 3/20/06) proved true. The executive board of Schering announced March 24 that it was looking favorably on Bayer's all-cash bid of €86 ($103) per share, a 29.7% bump over the March 10 closing price of $79.70.

"The executive board has carefully examined the proposal considering the interests of all stakeholders. The price of €86 per share, in connection with several other important commitments, is a good offer," said Dr. Hubertus Erlen, chairman of the executive board of Schering. "The businesses are complementary and follow the same strategy. Together they will be even more competitive internationally."

This view was echoed March 27 by the Schering supervisory board, which said it would recommend accepting the bid to the company's shareholders once the formal offer documents have been published and assessed.

Merck withdrew its bid in the wake of Bayer's offer, which places a $19.5 billion (€16.3 billion) value on the transaction, about $2.5 billion more than Merck was willing to pay.

Schering and Bayer have already begun filling in the details about what the new company might look like. Bayer Schering Pharma would be headquartered in Berlin and operate research facilities in Berlin and Wuppertal, Germany, as well as Richmond, VA, Berkeley, CA, and West Haven, CT. It would have annual sales approaching €10 billion ($12 billion).

Last year, the sale of x-ray and MR contrast media, along with radiopharmaceuticals, accounted for 26% of Schering sales. Net sales of Schering's Magnevist, Ultravist, and Iopamiron agents increased 8%, 5%, and 1%, respectively, over 2004.

Although Schering is viewed in imaging circles as a supplier of contrast agents, the company is best known as a maker of oral contraceptives and cancer drugs. Its merger with Bayer would forge one of the largest pharmaceutical companies in the world.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.